- Home
- TYG vs VNDA Comparison
TYG vs VNDA Comparison
Compare TYG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYG
- VNDA
- Stock Information
- Founded
- TYG 2003
- VNDA 2002
- Country
- TYG United States
- VNDA United States
- Employees
- TYG N/A
- VNDA N/A
- Industry
- TYG Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- TYG Finance
- VNDA Health Care
- Exchange
- TYG Nasdaq
- VNDA Nasdaq
- Market Cap
- TYG 429.9M
- VNDA 270.2M
- IPO Year
- TYG N/A
- VNDA 2006
- Fundamental
- Price
- TYG $40.45
- VNDA $4.74
- Analyst Decision
- TYG
- VNDA Buy
- Analyst Count
- TYG 0
- VNDA 1
- Target Price
- TYG N/A
- VNDA $13.00
- AVG Volume (30 Days)
- TYG 28.5K
- VNDA 692.7K
- Earning Date
- TYG 01-01-0001
- VNDA 11-06-2024
- Dividend Yield
- TYG 7.71%
- VNDA N/A
- EPS Growth
- TYG N/A
- VNDA N/A
- EPS
- TYG 9.77
- VNDA N/A
- Revenue
- TYG $13,618,248.00
- VNDA $182,022,000.00
- Revenue This Year
- TYG N/A
- VNDA $6.70
- Revenue Next Year
- TYG N/A
- VNDA $51.03
- P/E Ratio
- TYG $4.13
- VNDA N/A
- Revenue Growth
- TYG N/A
- VNDA N/A
- 52 Week Low
- TYG $27.25
- VNDA $3.30
- 52 Week High
- TYG $41.46
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- TYG 62.11
- VNDA 48.91
- Support Level
- TYG $40.05
- VNDA $4.68
- Resistance Level
- TYG $40.58
- VNDA $4.98
- Average True Range (ATR)
- TYG 0.59
- VNDA 0.17
- MACD
- TYG -0.12
- VNDA 0.05
- Stochastic Oscillator
- TYG 64.06
- VNDA 40.53
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.